181 related articles for article (PubMed ID: 32540170)
1. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine refractory angina registry: 1-year results.
Bennett NM; Iyer V; Arndt TL; Garberich RF; Traverse JH; Johnson RK; Poulose AK; Lips A; Morgan JM; Henry TD
Crit Pathw Cardiol; 2014 Sep; 13(3):96-8. PubMed ID: 25062392
[TBL] [Abstract][Full Text] [Related]
3. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy.
Slavich M; Maranta F; Fumero A; Godino C; Giannini F; Oppizzi M; Colombo A; Fragasso G; Margonato A
Am J Cardiol; 2016 May; 117(10):1558-1561. PubMed ID: 27055755
[TBL] [Abstract][Full Text] [Related]
6. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
[TBL] [Abstract][Full Text] [Related]
8. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine: a review of its use in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Coleman CI; Freemantle N; Kohn CG
BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
[TBL] [Abstract][Full Text] [Related]
12. Utility of ranolazine in chronic stable angina patients.
Patel PD; Arora RR
Vasc Health Risk Manag; 2008; 4(4):819-24. PubMed ID: 19065998
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Nguyen E; Coleman CI; Kohn CG; Weeda ER
Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
[TBL] [Abstract][Full Text] [Related]
14. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
18. Management of refractory angina pectoris.
Manchanda A; Aggarwal A; Aggarwal N; Soran O
Cardiol J; 2011; 18(4):343-51. PubMed ID: 21769814
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial.
Mehta PK; Sharma S; Minissian M; Harsch MR; Martinson M; Nyman JA; Shaw LJ; Bairey Merz CN; Wenger NK
J Womens Health (Larchmt); 2019 May; 28(5):573-582. PubMed ID: 30888919
[No Abstract] [Full Text] [Related]
20. Ranolazine: a review of its use in chronic stable angina pectoris.
Keating GM
Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]